Skip to main content

Drug Interactions between anifrolumab and pozelimab

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

anifrolumab pozelimab

Applies to: anifrolumab and pozelimab

GENERALLY AVOID: The use of anifrolumab, a type 1 interferon (IFN) receptor antagonist antibody with other biologic therapies, including B-cell-targeted therapies may increase the risk of infections. Anifrolumab alone has been reported to increase the risk of infections, including serious and fatal infections. However, concomitant use of anifrolumab with these therapies has not been studied. In the randomized, double-blind, placebo-controlled, phase 3 study of anifrolumab in adult subjects with active Systemic Lupus Erythematosus (SLE) (n=365), if patients had received treatment with a biologic agent, or a B-cell-depleting agent (e.g., ocrelizumab, ofatumumab, obinutuzumab, rituximab), they were required to complete a wash-out period of at least 5 half-lives prior to enrolment in the study.

MANAGEMENT: Until further information is available, anifrolumab is not recommended for use in combination with biologics with immunosuppressant effects, including B-cell-targeted therapies such as ocrelizumab, ofatumumab, obinutuzumab, or rituximab.

References

  1. (2022) "Product Information. Saphnelo (anifrolumab)." AstraZeneca Pty Ltd

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer